Afternoon Symposium - The Basics of Comprehensive Chromosomal Screening: What We All Need to Know for Our Practice

Presenters

The Basics of Comprehensive Chromosomal Screening: What We All Need to Know for Our Practice

Needs Assessment and Description
With the failure of fluorescence in situ hybridization (FISH) technology to demonstrate the expected clinical benefit from aneuploidy screening, new comprehensive chromosome-screening technologies need to set a higher standard of evidence before routine clinical implementation. This live course will provide clinicians and scientists with a basic understanding of comprehensive chromosome screening (CCS) technology and what evidence is necessary to demonstrate accuracy, reliability, safety, clinical predictive value and clinical efficacy. 

Learning Objectives
At the conclusion of this session, participants should be able to: 

1. Explain the differences among metaphase comparative genomic hybridization (CGH), array CGH, single nucleotide polymorphism (SNP) microarrays with parental support, quantitative SNP microarrays, and quantitative real time polymerase chain reaction (PCR) 
2. Identify the preclinical and clinical studies that are important for demonstrating accuracy, reliability, safety, and clinical predictive value and efficacy.

ACGME Competency
Medical Knowledge

TEST QUESTION:
After participating in this session, in my practice, in order to determine whether a method of comprehensive 24 chromosome aneuploidy screening is capable of being used to safely discard embryos after making a diagnosis of abnormal, I will complete the following study: 

1. Reanalysis of embryos diagnosed as aneuploid 
2. A randomized controlled trial 
3. A blinded non-selection study with DNA fingerprinting 
4. A study of the impact of embryo biopsy on reproductive potential 
5. Not applicable to my area of practice